Neuro Pain Medical Center

Summary

Neuro Pain Medical Center is a medical facility located in Fresno, California. This center is recognized for care of Migraine, Alzheimer's Disease, Epilepsy, Vestibular Migraine, Parkinson's Disease and other specialties. Neuro Pain Medical Center is involved with conducting 65 clinical trials across 63 conditions. There are 1 research doctors associated with this hospital, such as Perminder J Bhatia.

Top PIs

Clinical Trials running at Neuro Pain Medical Center

Migraine

Vestibular Migraine

Parkinson's Disease

Alzheimer's Dementia

Parkinson's disease

Alzheimer's Disease

Hyperacusis

Photophobia

Nausea and Vomiting

Diabetic Neuropathy

Eptinezumab

for Migraine

The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).

Recruiting

3 awards

Phase 4

2 criteria

Rimegepant

for Pediatric Migraine

This trial aims to test the safety of rimegepant, a medication for treating migraines. The study focuses on children and adolescents aged 6 to 17 years who experience moderate to severe migraines. Rimegepant works by blocking a protein that triggers migraine pain, helping to alleviate symptoms.

Recruiting

2 awards

Phase 3

8 criteria

Atogepant

for Migraine

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world. Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks. Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.

Recruiting

1 award

Phase 3

3 criteria